Stay updated with breaking news from Leukemia Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.
Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.
Harry P Erba, MD, PhD, discusses the safety profile and preliminary activity of the investigational menin inhibitor ziftomenib in acute myeloid leukemia.
The study's lead author said patients would experience improved quality of life due to fewer transfusions and fewer trips to the clinic to receive treatment.
Luspatercept-aamt led to a higher rate of sustained transfusion independence compared with erythropoiesis stimulating agents in patients with ESA-naïve, lower-risk myelodysplastic syndrome.